Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why
Structure Therapeutics Inc. (NASDAQ:GPCR) is among the 14 best booming stocks to buy right now.
Structure Therapeutics Inc. (GPCR)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 5,155,555 | $144,355,540 | 1.87% | |
| 2. | Deep Track Capital David Kroin | 4,215,811 | $118,042,708 | -18% | 3.29% |
| 3. | Biotechnology Value Fund / BVF Inc Mark Lampert | 3,203,917 | $89,709,676 | +81% | 3.64% |
| 4. | Baker Bros. Advisors Julian Baker And Felix Baker | 1,556,109 | $43,571,052 | -38% | 0.31% |
| 5. | Casdin Capital Eli Casdin | 1,555,000 | $43,540,000 | +27% | 3.63% |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 264,869 | $18,421,639 | 0.03% | |
| 2. | 252,600 | $17,568,330 | 4.23% | |
| 3. | 202,477 | $14,082,276 | 0% | |
| 4. | 84,324 | $5,864,734 | 0.18% | |
| 5. | 83,052 | $5,776,266 | 0.01% |
News See All
14 Best Booming Stocks to Buy Right Now
In a report released on January 9, Goldman Sachs said that it expects the index to rally 12% in 2026.
7 Stocks on Jim Cramer’s Radar Recently
“The market gets so angry over nothing. It's just plain irritable, very hard to please, like a 3-year-old child. But when you make it happy, the inner child giggles, and your stocks will soar.
H.C. Wainwright Upgrades Structure Therapeutics (GPCR) on Massive Arbitrage Opportunity for Oral GLP-1
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best up and coming stocks to buy according to Wall Street. On December 19, H.C.
10 Best Up and Coming Stocks to Buy According to Wall Street
On December 26, Thomson Nguyen, Saga Ventures co-founder and managing partner, joined 'Squawk Box' on CNBC to discuss the resurgence of the IPO market following a strong 2025 performance.
Structure Therapeutics (GPCR) Hits 52-Week High on Weight Loss Treatment Trial
Structure Therapeutics soared to a new 52-week high on Monday after announcing stellar topline results from its ongoing clinical program to test the efficacy of its therapy candidate, aleniglipron, in...
BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts
On November 10, 2025, BMO Capital reiterated its “Outperform” rating on Structure Therapeutics Inc. (NASDAQ:GPCR), setting a $100 price target.
10 Best Small-Cap Biotech Stocks to Buy According to Analysts
Small-cap biotech stocks are marking their latest resurgence, attracting renewed investor attention.
Structure Therapeutics Inc. (GPCR) Eyes Major 2025 Catalyst With Phase 2b Obesity Data
Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for metabolic diseases such as obesity and diabetes.
Top 10 AI-Powered Biotech Stocks to Buy Now
The head biotech analyst at Goldman Sachs, Salveen Richter, made an appearance on CNBC's "Squawk Box" on July 25 to discuss a variety of topics, including the status of the biotech industry and what to...
Hedge Fund Resource Center Billionaire Hedge Funds
